Amount of export($)
Number of employees
Established Year
Bioway Inc., is a novel drug development company that develops blood cancer treatments based on PI3K- delta inhibitor and NASH treatments based on SIRT1 activator. We have confirmed Best-in-Class in the fast- growing blood cancer market (CAGR of 11% or more) and expected to achieve First-in-Class status in the NASH treatment market as well (CAGR 64% or more). We have published AACR Chicago 2018 a poster based on pre-clinical results. We are actively engaged in business for license out (L/O). In relation to blood cancer development, Bioway Inc., has been selected for specialized investment and clinical support projects for new drug development by the Ministry of Health and Welfare.
Sanghoon Kwon
Tel.82-2-3295-5182
Email.sanghoon@bioway.co.kr
Sung Lyea Park
Tel.82-2-3295-5182
Email.slpark@bioway.co.kr
Da Woon Jeong
Tel.82-2-3295-5182
Email.dwjeong@bioway.co.kr